Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

This publication demonstrates how population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor being studied in patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Researchers analyzed data from more than 500 patients across Phase 1 and Phase 2 studies to characterize how the therapy is absorbed, distributed, and eliminated in the body, while also evaluating how patient-specific factors such as age, body weight, renal function, hepatic function, and concomitant medications influenced drug exposure. The analysis found no clinically meaningful covariates that would require dose adjustments, supporting a consistent dosing strategy across a broad patient population.

The study also assessed the relationship between drug exposure, efficacy, and safety outcomes. Higher exposure levels were associated with improved probability of treatment response, while maintaining an acceptable safety profile at the recommended dose. These findings supported selection of the 65 mg daily dose as the recommended Phase 2 regimen and reinforced its overall benefit-risk profile.

Overall, the publication highlights the value of model-informed drug development (MIDD) approaches in oncology, demonstrating how integrated pharmacometric analyses can inform dose optimization, evaluate variability across patient populations, and support more confident development and regulatory decision-making.